Conference Coverage

Smartphone app aimed at disrupting first-episode psychosis shows promise

View on the News

Intervening early will set stage for treatments

One of the most compelling aspects to schizophrenia, the most serious of mental disorders, is its age of onset in late adolescence and early adulthood. Intervening early on has good logic and good sense on its side. Nothing can be more important than giving attention to patients and families early on. However, it still remain unknown what biological processes trigger the disorder, and to date there are no data suggesting that we are able to slow the illness progression. Nevertheless, focusing early will teach us about the illness and set the stage when the next generation of biological treatments emerge.

David Pickar, MD, is a psychiatrist and former (retired) director of intramural research at the National Institute of Mental Health. In addition, Dr. Pickar is adjunct professor of psychiatry at Johns Hopkins University, Baltimore, and at the Uniformed Services University of the Health Sciences, Bethesda, Md.


 

EXPERT ANALYSIS FROM THE 2016 NIMH CONFERENCE ON MENTAL HEALTH SERVICES RESEARCH

References

In addition to the support from the online community, trial participants spend an average of 20 minutes with the coaching staff, making the model a “very low resource” one, according to Dr. Schlosser.

PRIME is expected to complete in the spring 2018, at which time the data collected potentially will be used to refine user-designed apps for use in other mental disorders, Dr. Schlosser said.

“I want to promote a digital system of care so that we can move immediately from when we identify a person is at risk to immediately giving them support. I think we can improve things so that we don’t just have equivalent levels of care but optimal ones,” Dr. Schlosser told the audience. “What we have had as our system of care to date isn’t working.”

Dr. Schlosser did not have any relevant disclosures.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

Pages

Recommended Reading

Rediscovering clozapine: After a turbulent history, current guidance on initiating and monitoring
MDedge Psychiatry
Using lipid guidelines to manage metabolic syndrome for patients taking an antipsychotic
MDedge Psychiatry
Rediscovering clozapine
MDedge Psychiatry
Statement warns of drugs causing or exacerbating heart failure
MDedge Psychiatry
Childhood trauma, cannabis use disorders examined in schizophrenia
MDedge Psychiatry
Withdrawing risperidone spikes risk for psychotic relapse in hallucinating Alzheimer’s patients
MDedge Psychiatry
Rediscovering clozapine: Adverse effects develop—what should you do now?
MDedge Psychiatry
When to adjust the dosing of psychotropics in patients with renal impairment
MDedge Psychiatry
Adjusting the dosing of antipsychotics and other psychotropics in renal disease
MDedge Psychiatry
Scant evidence for how to avoid seclusion, restraint in psychiatric patients
MDedge Psychiatry